1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with alpha-aminopyridine in 1 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (alpha-aminopyridine) | Trials (alpha-aminopyridine) | Recent Studies (post-2010) (alpha-aminopyridine) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 5,813 | 460 | 3,246 |
| Protein | Taxonomy | 1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50) | alpha-aminopyridine (IC50) |
|---|---|---|---|
| Botulinum neurotoxin type A | Clostridium botulinum | 1.8 | |
| Nitric oxide synthase, endothelial | Homo sapiens (human) | 2.8 | |
| Nitric oxide synthase, brain | Homo sapiens (human) | 6 | |
| Nitric oxide synthase, brain | Rattus norvegicus (Norway rat) | 9 | |
| Nitric oxide synthase, inducible | Homo sapiens (human) | 1.9 | |
| Phosphatidylinositol 4-kinase alpha | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase type 2-beta | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase type 2-alpha | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase beta | Homo sapiens (human) | 7.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gollash, M; Ignat'eva, VB; Kulikov, VI; Lipatkina, LIu; Vornovitskiĭ, EG | 1 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and alpha-aminopyridine
| Article | Year |
|---|---|
[Cardiodepressive effect of platelet activating factor].
Topics: Action Potentials; Aminopyridines; Animals; Calcium; Guinea Pigs; Heart; Heart Atria; Histamine; In Vitro Techniques; Membrane Potentials; Myocardial Contraction; Platelet Activating Factor; Potassium | 1989 |